SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long ...

Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the ...

I am a 66-year-old white male who is active and relatively healthy. I have recently been diagnosed with prostate cancer. One ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price ...

This case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, as well as highlights the unique ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Juvenile idiopathic arthritis is the most common chronic systemic disease associated with uveitis in childhood. Uveitis occurs in 11–22% of children with juvenile idiopathic arthritis.1 Due to the ...

Among those treated for sarcoidosis in the year following diagnosis, 60% used steroids alone, 13% nonsteroidal immunosuppressives alone, and 27% received both. About 43% of patients with sarcoidosis ...

Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Coherus Biosciences (CHRS – Research Report). The associated price ...

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

The guidelines are a first-of-its-kind effort to establish recommendations for the medical management of HS in seven ...